Sign in or create an account to add this stock to your watchlist.
About Vivus (NASDAQ:VVUS)
VIVUS, Inc., a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also involved in developing Qsymia, which has been completed Phase II studies for the treatment of various diseases, including obstructive sleep apnea and diabetes, nonalcoholic steatohepatitis and fatty liver disease, hyperlipidemia, and hypertension, as well as Tacrolimus that has been completed Phase IIa studies for the treatment of pulmonary arterial hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin Chemie AG to commercialize and promote STENDRA. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:VVUS
CUSIP92855110
Phone650-934-5200
Debt
Debt-to-Equity Ratio-12.06
Current Ratio8.67
Quick Ratio7.94
Price-To-Earnings
Trailing P/E Ratio-2.71
Forward P/E Ratio-1.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$65.37 million
Price / Sales1.28
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-8.74
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-30,510,000.00
Net Margins-79.80%
Return on Equity-843.43%
Return on Assets-15.08%
Miscellaneous
Employees52
Outstanding Shares106,050,000
Vivus (NASDAQ:VVUS) Frequently Asked Questions
What is Vivus' stock symbol?
Vivus trades on the NASDAQ under the ticker symbol "VVUS."
How were Vivus' earnings last quarter?
Vivus (NASDAQ:VVUS) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The biopharmaceutical company had revenue of $11.90 million for the quarter. Vivus had a negative return on equity of 843.43% and a negative net margin of 79.80%. View Vivus' Earnings History.
When is Vivus' next earnings date?
Who are some of Vivus' key competitors?
Some companies that are related to Vivus include Athersys (ATHX), Catalyst Biosciences (CBIO), Arbutus Biopharma (ABUS), ArQule (ARQL), Corium International (CORI), Corvus Pharmaceuticals (CRVS), Seres Therapeutics (MCRB), DURECT (DRRX), BioSpecifics Technologies (BSTC), Minerva Neurosciences (NERV), Tyme Technologies (TYME), Biofrontera (BFRA), Sienna Biopharmaceuticals (SNNA), Aquinox Pharmaceuticals (AQXP) and Kadmon (KDMN).
Who are Vivus' key executives?
Vivus' management team includes the folowing people:
- Mr. Mark K. Oki, CFO & Chief Accounting Officer (Age 49)
- Mr. John L. Slebir Esq., Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 53)
- Dr. Santosh T. Varghese M.D., Chief Medical Officer (Age 48)
- Mr. Seth H. Z. Fischer, Strategic Adviser (Age 62)
- Mr. Thomas B. King, Interim CEO & Director (Age 63)
Has Vivus been receiving favorable news coverage?
News headlines about VVUS stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vivus earned a daily sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Vivus?
Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vivus' stock price today?
One share of VVUS stock can currently be purchased for approximately $0.7867.
How big of a company is Vivus?
Vivus has a market capitalization of $84.84 million and generates $65.37 million in revenue each year. The biopharmaceutical company earns $-30,510,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Vivus employs 52 workers across the globe.
How can I contact Vivus?
Vivus' mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]
MarketBeat Community Rating for Vivus (VVUS)
MarketBeat's community ratings are surveys of what our community members think about Vivus and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vivus (NASDAQ:VVUS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | N/A |
| Consensus Rating Score: | N/A | N/A | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Vivus (NASDAQ:VVUS) Consensus Price Target History
Vivus (NASDAQ:VVUS) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/25/2016 | WallachBeth Capital | Set Price Target | Buy | $2.80 | N/A |  |
(Data available from 5/22/2016 forward)
Vivus (NASDAQ:VVUS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vivus (NASDAQ VVUS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 21.15%
Vivus (NASDAQ VVUS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | John P Amos | CEO | Buy | 540,000 | $0.56 | $302,400.00 | 810,000 | |
| 5/14/2018 | John P Amos | CEO | Buy | 540,000 | $0.52 | $280,800.00 | 270,000 | |
| 5/11/2018 | John P Amos | CEO | Buy | 270,000 | $0.52 | $140,400.00 | 270,000 | |
| 4/3/2018 | Santosh T Varghese | Insider | Sell | 390 | $0.34 | $132.60 | | |
| 1/31/2018 | Santosh T Varghese | Insider | Sell | 491 | $0.43 | $211.13 | 71,805 | |
| 1/1/2018 | Santosh T Varghese | Insider | Sell | 444 | $0.51 | $226.44 | 72,296 | |
| 10/3/2017 | Santosh T Varghese | Insider | Sell | 434 | $0.97 | $420.98 | | |
| 7/3/2017 | Santosh T Varghese | Insider | Sell | 423 | $1.23 | $520.29 | 73,174 | |
| 4/4/2017 | Santosh T Varghese | Insider | Sell | 440 | $1.08 | $475.20 | 73,597 | |
| 3/10/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 1,149,400 | $1.16 | $1,333,304.00 | | |
| 3/7/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 192,800 | $1.08 | $208,224.00 | | |
| 3/2/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 160,100 | $1.13 | $180,913.00 | | |
| 2/27/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 333,000 | $1.14 | $379,620.00 | | |
| 2/22/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 161,800 | $1.11 | $179,598.00 | | |
| 2/16/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 305,090 | $1.10 | $335,599.00 | | |
| 2/13/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 176,410 | $1.11 | $195,815.10 | | |
| 2/8/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 563,527 | $1.06 | $597,338.62 | | |
| 2/7/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 6,200 | $1.11 | $6,882.00 | | |
| 2/6/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 28,027 | $1.10 | $30,829.70 | | |
| 2/3/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 78,633 | $1.12 | $88,068.96 | | |
| 1/28/2017 | Santosh T Varghese | Insider | Sell | 429 | $1.11 | $476.19 | 74,037 | |
| 12/31/2016 | Santosh T Varghese | Insider | Sell | 13,790 | $1.12 | $15,444.80 | 74,830 | |
| 10/1/2016 | Santosh T Varghese | Insider | Sell | 710 | $1.14 | $809.40 | 88,610 | |
| 8/2/2016 | Santosh T Varghese | Insider | Sell | 12,559 | $1.07 | $13,438.13 | 88,966 | |
| 7/1/2016 | Santosh T Varghese | VP | Sell | 366 | $1.21 | $442.86 | 101,525 | |
| 4/7/2016 | Santosh T Varghese | Insider | Sell | 329 | $1.65 | $542.85 | 101,891 | |
| 4/1/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 2,160 | $1.40 | $3,024.00 | | |
| 3/31/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 383,300 | $1.29 | $494,457.00 | | |
| 3/28/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 202,000 | $1.12 | $226,240.00 | | |
| 3/16/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 500,000 | $1.21 | $605,000.00 | | |
| 1/1/2016 | John L Slebir | SVP | Sell | 2,973 | $3.04 | $9,037.92 | 44,555 | |
| 1/8/2015 | North Tide Capital, Llc | Major Shareholder | Buy | 500,000 | $3.12 | $1,560,000.00 | | |
| 1/6/2015 | North Tide Capital, Llc | Major Shareholder | Buy | 476,800 | $3.04 | $1,449,472.00 | | |
| 1/2/2015 | North Tide Capital, Llc | Major Shareholder | Buy | 523,200 | $2.90 | $1,517,280.00 | | |
| 3/11/2014 | Seth H.Z. Fischer | CEO | Buy | 3,080 | $6.07 | $18,695.60 | 3,080 | |
| 11/11/2013 | Alexander Denner | Director | Buy | 566,844 | $8.59 | $4,869,189.96 | | |
| 9/5/2013 | Timothy E Morris | CFO | Sell | 10,654 | $11.95 | $127,315.30 | | |
| 9/4/2013 | Michael J Astrue | Director | Buy | 10,000 | $11.96 | $119,600.00 | | |
| 6/27/2013 | Jon C Biro | Insider | Buy | 2,000 | $12.85 | $25,700.00 | | |
| 5/29/2013 | Ernest Mario | Director | Buy | 15,000 | $14.68 | $220,200.00 | | |
| 8/20/2012 | Ernest Mario | Director | Buy | 5,000 | $20.75 | $103,750.00 | | |
| 8/10/2012 | Ernest Mario | Director | Buy | 20,000 | $21.74 | $434,800.00 | | |
(Data available from 1/1/2013 forward)
Vivus (NASDAQ VVUS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | -$0.11 Earnings Per Share Expected for Vivus (VVUS) This Quarter
www.americanbankingnews.com - May 21 at 3:12 PM |
 | BRIEF-Vivus Says Got Letter From Nasdaq Informing that it Granted Co's Request For Continued Listing, On Conditions
www.reuters.com - May 18 at 11:01 AM |
 | VIVUS (VVUS) Adds to Gains as CEO Buys Over 1M Shares
www.streetinsider.com - May 18 at 11:01 AM |
| Insider Buying: Vivus (VVUS) CEO Purchases 540,000 Shares of Stock
www.americanbankingnews.com - May 17 at 8:15 PM |
| Zacks Investment Research Upgrades Vivus (VVUS) to "Buy"
www.americanbankingnews.com - May 16 at 1:35 PM |
| Form 4 VIVUS INC For: May 11 Filed by: Amos John P.
www.streetinsider.com - May 16 at 10:23 AM |
| Vivus (VVUS) CEO John P. Amos Buys 540,000 Shares
www.americanbankingnews.com - May 15 at 10:10 PM |
| Insider Buying: Vivus (VVUS) CEO Buys 270,000 Shares of Stock
www.americanbankingnews.com - May 15 at 10:10 PM |
 | VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
www.zacks.com - May 10 at 9:56 AM |
 | Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:56 AM |
| Vivus (VVUS) Issues Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 9 at 1:58 PM |
 | Vivus' (VVUS) CEO John Amos on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:44 AM |
| Vivus: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:44 AM |
| Vivus beats by $0.01, misses on revenue
seekingalpha.com - May 8 at 4:19 PM |
 | VIVUS Reports First Quarter 2018 Financial Results
www.globenewswire.com - May 8 at 4:16 PM |
| VIVUS Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:16 PM |
| VIVUS Announces Date of 2018 Annual Meeting
finance.yahoo.com - May 4 at 4:18 PM |
| Vivus (VVUS) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - May 4 at 11:04 AM |
| Form 4 VIVUS INC For: Apr 30 Filed by: Oki Mark K
www.streetinsider.com - May 3 at 9:38 AM |
| VIVUS, Inc., New Team, New Acquisition Agreement, New Product, Analysts Review
finance.yahoo.com - May 3 at 9:38 AM |
| Vivus (VVUS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 2:02 PM |
| Today’s Research Reports on Stocks to Watch: Avinger and VIVUS
finance.yahoo.com - May 2 at 9:39 AM |
| VIVUS (VVUS) Names John Amos as CEO
www.streetinsider.com - May 1 at 9:41 AM |
| BRIEF-Vivus Expands Its Commercial Product Portfolio With The Acquisition Of Pancreaze
www.reuters.com - May 1 at 9:41 AM |
| BRIEF-Vivus Restructures Debt And Gains Access To New Capital
www.reuters.com - May 1 at 9:41 AM |
| VIVUS (VVUS) Reports Acquisition of PANCREAZE
www.streetinsider.com - May 1 at 9:41 AM |
| VIVUS Restructures Debt and Gains Access to New Capital
finance.yahoo.com - May 1 at 9:41 AM |
| VIVUS Strengthens Executive Leadership Team
finance.yahoo.com - May 1 at 9:41 AM |
| VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®
finance.yahoo.com - May 1 at 9:41 AM |
| Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
finance.yahoo.com - April 26 at 4:14 PM |
| VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018
finance.yahoo.com - April 25 at 4:13 PM |
| Vivus (VVUS) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:24 AM |
| Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?
finance.yahoo.com - April 12 at 10:39 AM |
 | Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and ...
www.prnewswire.com - April 10 at 4:13 PM |
| Vivus (VVUS) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 2 at 10:23 PM |
| Zacks: Brokerages Anticipate VIVUS, Inc. (VVUS) to Announce -$0.11 Earnings Per Share
www.americanbankingnews.com - March 31 at 8:32 AM |
| Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed
seekingalpha.com - March 24 at 4:36 PM |
| BRIEF-Vivus Reports Qtrly loss Per Share $0.10
www.reuters.com - March 14 at 12:37 PM |
| VIVUS (VVUS) Issues Earnings Results
www.americanbankingnews.com - March 14 at 12:20 PM |
| VIVUS Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 13 at 4:28 PM |
| Vivus reports 4Q loss
finance.yahoo.com - March 13 at 4:28 PM |
| VIVUS (VVUS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM |
| Brokerages Expect VIVUS, Inc. (VVUS) to Announce -$0.13 EPS
www.americanbankingnews.com - February 25 at 5:20 AM |
| Kadmon (KDMN) and VIVUS (VVUS) Critical Analysis
www.americanbankingnews.com - February 20 at 4:31 PM |
| Head to Head Survey: Transition Therapeutics (TTHI) and VIVUS (VVUS)
www.americanbankingnews.com - February 10 at 7:14 PM |
| VIVUS (VVUS) Raised to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 12:38 PM |
| Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPS
www.americanbankingnews.com - January 22 at 11:30 AM |
 | Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS
www.bizjournals.com - January 17 at 10:30 AM |
| VIVUS (VVUS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 1:16 PM |
| -$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter
www.americanbankingnews.com - January 5 at 11:36 AM |
Vivus (NASDAQ:VVUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vivus (NASDAQ:VVUS) Income Statement, Balance Sheet and Cash Flow Statement
Vivus (NASDAQ VVUS) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
